MDGL - Madrigal Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Madrigal Pharmaceuticals, Inc.

Four Tower Bridge
Suite 400 200 Barr Harbor Drive
West Conshohocken, PA 19428
United States
484-380-9263
http://www.madrigalpharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees17

Key Executives

NameTitlePayExercisedYear Born
Dr. Paul A. FriedmanChairman & CEO721.17kN/A1943
Dr. Rebecca A. TaubFounder, Pres of R&D & Director610.75kN/A1952
Mr. Marc R. SchneebaumSr. VP & CFO617.9k1.6M1954
Mr. Brian J. LynchSr. VP & Gen. CounselN/AN/A1961
Mr. Thomas W. HareSr. VP of Clinical ManagementN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.

Corporate Governance

Madrigal Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.